
Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial
Keywords: IV، داخل وریدی; denosumab; osteoclasts; prostatic neoplasms; RANK ligand; urinary N-telopeptide of type I collagen; humanAE, adverse event; BCE, bone collagen equivalents; BP, bisphosphonates; Cr, creatinine; ECOG, Eastern Cooperative Oncology Group; IV, intravenous; Q4W